Keywords: Pfizer, Medivation, Dimebon, Huntington disease, Alzheimer's, Phase III failure

Pfizer and Medivation’s Dimebon also flops in Huntington disease

Article | 12 April 2011

Print This

Global drug behemoth Pfizer (NYSE: PFE) and partner Medivation (Nasdaq: MDVN) said yesterday that results from the Phase III HORIZON ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in